CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer

CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer

Abstract Background Growing evidence shows that the reprogramming of fatty acid (FA) metabolism plays a key role in HER2-positive (HER2 +) breast cancer (BC) aggressiveness, therapy resistance and cancer stemness. In particular, HER2 + BC has been defined as a "lipogenic disease" due to th...

Full description

Saved in:
Bibliographic Details
Main Authors: Lorenzo Castagnoli, Alma Franceschini, Valeria Cancila, Matteo Dugo, Martina Bigliardi, Claudia Chiodoni, Paolo Toneguzzo, Viola Regondi, Paola A. Corsetto, Filippo Pietrantonio, Serena Mazzucchelli, Fabio Corsi, Antonio Belfiore, Antonio Vingiani, Giancarlo Pruneri, Francesca Ligorio, Mario P. Colombo, Elda Tagliabue, Claudio Tripodo, Claudio Vernieri, Tiziana Triulzi, Serenella M. Pupa
Format: Article
Language:English
Published: BMC 2025-01-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
HER2
Fatty Acid Uptake
CD36
Cancer Stem Cells
Wnt pathway
Resistance to anti-HER2 therapy
Online Access:https://doi.org/10.1186/s13046-025-03276-z
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s13046-025-03276-z

Similar Items